Eloralintide — Safety, Research, Risks & Legal Status

Not medical advice. Eloralintide is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	LY3841136
Category	Peptide (research chemical)
Developer	Eli Lilly and Company
Development code	LY3841136
Receptor selectivity	12-fold AMY1R over CTR; 11-fold AMY1R over AMY3R
Half-life	Approximately 2 weeks; supports once-weekly subcutaneous dosing
Development stage (mid-2026)	Phase 3 (ENLIGHTEN-1, ENLIGHTEN-2); Phase 2 results published in The Lancet 2025
Phase 2 sample size	263 adults with obesity or overweight without T2D; 48-week trial duration
US legal status	Not FDA-approved. Investigational new drug (IND) under active Phase 3 clinical development by Eli Lilly and Company. Not approved for human use outside of clinical trials. Not available as a supplement or over-the-counter product.

What is Eloralintide?

Eloralintide (development code LY3841136) is a synthetic, selective, long-acting amylin receptor agonist peptide developed by Eli Lilly and Company for the treatment of obesity, with and without type 2 diabetes. It is a modified polypeptide analog of the endogenous pancreatic hormone amylin, engineered for preferential binding to the AMY1R receptor subtype and a pharmacokinetic profile supporting once-weekly subcutaneous administration. It is currently in Phase 3 clinical trials and has no approved therapeutic indication.

How it works

Eloralintide acts as a selective agonist at the amylin receptor subtype AMY1R, exhibiting approximately 12-fold selectivity for AMY1R over the calcitonin receptor (CTR) and 11-fold selectivity over AMY3R. Endogenous amylin is co-secreted with insulin from pancreatic beta cells and regulates satiety, gastric emptying, and glucagon secretion. By selectively engaging AMY1R, eloralintide is designed to produce the weight-reducing and metabolic effects attributed to amylin signaling while reducing off-target activity at CTR and AMY3R -- receptors implicated in the aversive side effects (including conditioned taste aversion) observed with non-selective amylin analogs such as cagrilintide. Its modified polypeptide structure confers an approximate two-week half-life, enabling once-weekly dosing.

Background & history

Amylin-based obesity pharmacology has been explored since the early 1990s following characterization of the endogenous hormone. First-generation amylin analogs (pramlintide, approved 2005 for diabetes as Symlin) required multiple daily injections and were non-selective across receptor subtypes. The rationale for selective AMY1R agonism as a differentiation strategy drove development of long-acting, receptor-selective analogs. Eli Lilly advanced LY3841136 (eloralintide) from discovery into Phase 1 trials (NCT05295940), completing single-dose studies in 48 healthy volunteers. Phase 2 (NCT06230523) enrolled 263 adults with obesity or overweight without type 2 diabetes over 48 weeks, with results published in The Lancet in 2025. Phase 3 trials under the ENLIGHTEN program (ENLIGHTEN-1 for obesity without T2D; ENLIGHTEN-2, NCT07282600, for obesity with T2D) were enrolling as of 2025-2026. No NDA submission timeline has been announced as of mid-2026.

What the research says

Human clinical data exist at Phase 1 and Phase 2 levels, with Phase 3 ongoing. Phase 1 (single-dose, 4-week follow-up in healthy volunteers): 4 mg produced approximately -2.5% body weight versus +0.6% for placebo; 12 mg produced approximately -4.4% versus +0.6% for placebo. Phase 2 (48-week, continuous dosing in adults with obesity or overweight without T2D): meaningful body weight reductions that had not plateaued by week 48; improvements in cardiometabolic markers including waist circumference, blood pressure, lipid profiles, glycemic control, and inflammatory markers were reported. Dose titration (3 mg to 6 mg to 9 mg) substantially improved GI tolerability relative to fixed higher-dose regimens. Animal model data indicate significantly lower conditioned taste aversion versus non-selective amylin agonists. Phase 3 results are not yet available; the compound's ultimate efficacy and safety profile at the population level remains to be established.

Reported effects

Body weight reduction: observed in Phase 1 (single-dose) and Phase 2 (48-week) human trials, with reductions not plateaued at 48 weeks in the latter
Decreased appetite and increased satiety via AMY1R agonism, consistent with amylin receptor pharmacology
Improved cardiometabolic markers in Phase 2: reductions in waist circumference, blood pressure, and lipid levels reported
Glycemic improvements and reductions in inflammation markers observed in Phase 2 participants
Slower gastric emptying, a known effect of amylin receptor activation, contributing to satiety signaling
Lower conditioned taste aversion versus non-selective amylin agonists in animal models - human generalizability requires further study

Dosing & administration (informational)

Phase 1 and Phase 2 clinical trial dose ranges used in published human studies include single doses of 4 mg and 12 mg (Phase 1) and titrated regimens of 3 mg to 6 mg to 9 mg subcutaneously once weekly (Phase 2). These figures are drawn from trial protocols and published literature for informational reference only. They do not constitute a dosing protocol and should not be used to guide self-administration. Optimal dosing in any approved indication, if approval is eventually granted, will be defined by the product label. Consult a licensed clinician for any therapeutic decisions.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Gastrointestinal adverse events are dose-dependent and the most common class of side effects; include nausea (32.7% in highest fixed-dose Phase 2 groups), vomiting, and diarrhea
Fatigue reported in approximately 26.9% of higher-dose Phase 2 participants
Dose titration strategy (3 mg to 6 mg to 9 mg) reduced GI side effects to rates similar to placebo in Phase 2
No unexpected or serious safety signals beyond dose-related GI symptoms were reported in Phase 1 or Phase 2; Phase 3 safety data are not yet available
Theoretical risk of off-target calcitonin receptor activation (bone effects, emesis) is reduced by design relative to non-selective amylin analogs, but long-term human safety data do not yet exist
As an unapproved investigational peptide, long-term safety, rare adverse events, and drug interaction profiles have not been fully characterized; use outside of clinical trials is not established as safe

Drug & supplement interactions

Who should avoid it

Self-administration outside of an IRB-approved, sponsor-monitored clinical trial
Use in pregnancy or lactation - no safety data exist in these populations
Use in individuals with a personal or family history of medullary thyroid carcinoma or MEN2 - theoretical concern by class analogy, not yet formally characterized for this compound
Concurrent use with other agents affecting gastric emptying without clinician oversight
Sourcing from any vendor outside of the clinical trial supply chain - purity and identity cannot be assured

How it is commonly combined

No evidence-based stacking data exist for eloralintide as of mid-2026. The ENLIGHTEN Phase 3 program includes combination and liver function subgroup assessments, and combination studies with GLP-1 receptor agonists appear to be under evaluation by Eli Lilly, but results are not publicly available. Any combination use outside of a clinical trial is speculative and not supported by published human safety data.

Legal & regulatory. Not FDA-approved. Investigational new drug (IND) under active Phase 3 clinical development by Eli Lilly and Company. Not approved for human use outside of clinical trials. Not available as a supplement or over-the-counter product.

Quality & harm reduction

E
l
o
r
a
l
i
n
t
i
d
e
i
s
a
p
r
o
p
r
i
e
t
a
r
y
i
n
v
e
s
t
i
g
a
t
i
o
n
a
l
p
e
p
t
i
d
e
m
a
n
u
f
a
c
t
u
r
e
d
b
y
E
l
i
L
i
l
l
y
a
n
d
C
o
m
p
a
n
y
u
n
d
e
r
I
N
D
c
o
n
d
i
t
i
o
n
s
;
p
h
a
r
m
a
c
e
u
t
i
c
a
l
-
g
r
a
d
e
m
a
t
e
r
i
a
l
i
s
a
v
a
i
l
a
b
l
e
o
n
l
y
w
i
t
h
i
n
s
p
o
n
s
o
r
e
d
c
l
i
n
i
c
a
l
t
r
i
a
l
s
.
N
o
l
e
g
i
t
i
m
a
t
e
c
o
m
m
e
r
c
i
a
l
s
o
u
r
c
e
e
x
i
s
t
s
f
o
r
t
h
e
g
e
n
e
r
a
l
p
u
b
l
i
c
.
A
n
y
e
l
o
r
a
l
i
n
t
i
d
e
o
f
f
e
r
e
d
o
u
t
s
i
d
e
o
f
a
r
e
g
i
s
t
e
r
e
d
c
l
i
n
i
c
a
l
t
r
i
a
l
c
o
n
t
e
x
t
w
o
u
l
d
b
e
o
f
u
n
v
e
r
i
f
i
e
d
i
d
e
n
t
i
t
y
,
p
u
r
i
t
y
,
a
n
d
p
o
t
e
n
c
y
.
I
n
d
e
p
e
n
d
e
n
t
a
n
a
l
y
t
i
c
a
l
v
e
r
i
f
i
c
a
t
i
o
n
w
o
u
l
d
b
e
e
s
s
e
n
t
i
a
l
b
e
f
o
r
e
a
n
y
r
e
s
e
a
r
c
h
u
s
e
,
t
h
o
u
g
h
h
u
m
a
n
s
e
l
f
-
a
d
m
i
n
i
s
t
r
a
t
i
o
n
o
u
t
s
i
d
e
t
r
i
a
l
s
i
s
o
u
t
s
i
d
e
t
h
e
b
o
u
n
d
s
o
f
t
h
e
c
u
r
r
e
n
t
r
e
g
u
l
a
t
o
r
y
f
r
a
m
e
w
o
r
k
.

Safer, legal alternative we recommend

Big Berb Energy. For a natural approach to the same metabolic/blood-sugar goal, our Berberine is a well-studied legal supplement.

See our recommended pick

Find Eloralintide →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

What is eloralintide and how does it differ from older amylin analogs?

Eloralintide is a synthetic peptide designed as a selective AMY1R agonist, with roughly 12-fold preference for AMY1R over the calcitonin receptor. Earlier amylin analogs such as pramlintide are non-selective across receptor subtypes. The selectivity is intended to preserve the satiety and weight-reducing effects of amylin signaling while reducing off-target receptor activity linked to aversive side effects like conditioned taste aversion, which was documented in animal models. Whether this translates to meaningfully better tolerability in humans at the population scale will depend on Phase 3 results.

What does the human clinical evidence show so far?

Phase 1 data (single-dose in 48 healthy volunteers) showed dose-dependent weight loss of approximately 2.5% to 4.4% versus placebo at 4 mg and 12 mg respectively over 4 weeks. Phase 2 data (48 weeks, 263 adults with obesity or overweight, no T2D) showed meaningful body weight reductions that had not plateaued at week 48, along with improvements in cardiometabolic markers. Phase 3 results from the ENLIGHTEN trials are not yet published as of mid-2026.

What are the main side effects seen in trials?

Gastrointestinal events - nausea, vomiting, diarrhea - were the most common adverse effects and were dose-dependent. In the highest fixed-dose Phase 2 groups, nausea was reported in approximately 32.7% of participants and fatigue in approximately 26.9%. Importantly, a dose titration approach (starting at 3 mg and escalating to 9 mg) reduced GI side effects to rates comparable to placebo in Phase 2. No unexpected serious safety signals were reported in Phase 1 or 2; long-term safety data await Phase 3 completion.

Is eloralintide available to the public or for purchase online?

No. Eloralintide is an unapproved investigational new drug available only within Eli Lilly-sponsored clinical trials. There is no legitimate commercial supply chain for the general public. Any product sold online under this name or LY3841136 would be of unverified identity and purity and is not sanctioned for human use.

Can I get a dosing recommendation for eloralintide?

No dosing recommendation can be provided here. The dose ranges published in Phase 1 and Phase 2 trial literature are described in the dosing context field for informational reference only. They were administered in controlled clinical settings with medical monitoring. Consult a licensed clinician or enroll in a registered clinical trial through ClinicalTrials.gov if you are interested in access.

How does eloralintide compare to GLP-1 receptor agonists like semaglutide?

Eloralintide works through a completely different mechanism - amylin receptor agonism rather than GLP-1 receptor agonism. GLP-1 agonists like semaglutide have completed Phase 3 trials, received FDA approval, and have extensive real-world safety data. Eloralintide is earlier in development with Phase 3 data pending. Eli Lilly's ENLIGHTEN program includes combination studies, suggesting the two mechanisms may be evaluated together. Direct efficacy comparisons between eloralintide and approved GLP-1 agents in head-to-head trials have not been published as of mid-2026.

References & further reading

PubMed: Eloralintide LY3841136 novel amylin receptor agonist discovery clinical proof of concept PMC12640043
PubMed: Eloralintide selective long-acting amylin receptor agonist Phase 1 proof of concept PMC12992164
ClinicalTrials.gov: NCT06230523 eloralintide Phase 2 obesity overweight
ClinicalTrials.gov: NCT07282600 ENLIGHTEN-2 eloralintide obesity type 2 diabetes Phase 3
The Lancet: Eloralintide selective amylin receptor agonist treatment obesity 48-week phase 2 trial 2025 PIIS0140-6736(25)02155-5